Abstract: 【ABSTRACT】Objective: To investigate the clinical therapeutic effect of DC-CIK cells in patients with middle and advanced non small cell lung cancer(NSCLC). Methods: 80 cases of middle and advanced NSCLC patients according to treatment methods are divided into chemotherapy group (group A) and DC-CIK combined with chemotherapy group (group B), 40 cases in each; group A by routine chemotherapy platinum class hydrochloride combined with gemcitabine four courses of treatment; group B at the same time the implementation of DC-CIK cell treatment. The therapeutic effect and side effects of two groups were compared at 4 months. No disease progression and mortality were compared at 1 years of follow-up. Results: Group B, CR8 cases, PR9 cases, SD17 cases, PD 6 cases, group A, CR6 cases, PR7 cases, SD15 cases, PD12 cases. The clinical efficiency and clinical benefit rate of group B was significantly higher than that of group A(P＜0.05). There was no significant difference in bone marrow suppression, liver and renal function between the two groups. Group A(P＜0.05) was significantly lower than the group B(P＜0.05) in the gastrointestinal reaction, fatigue and loss of appetite. The patients were followed up for 1 years without disease progression (PFS) 7.4 months, group A, PFS was 6.1 months (P＜0.05). There was no significant difference in 1 year mortality rate between the two groups. Conclusion: Early application of DC-CIK can improve the clinical efficacy, reduce treatment toxicity, improve immunity and the quality of life of patients combined with chemotherapy, radiotherapy, and targeted drugs in the treatment of Middle and advanced NSCLC.